Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic
Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, wh...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2022-03-01
|
| Series: | Turkderm Turkish Archives of Dermatology and Venereology |
| Subjects: | |
| Online Access: | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-47817&look4= |
| _version_ | 1797915277752532992 |
|---|---|
| author | Sinem Örnek Aslı Bilgiç Serkan Yazici Dilek Bayramgürler Hatice Şanlı Nahide Onsun |
| author_facet | Sinem Örnek Aslı Bilgiç Serkan Yazici Dilek Bayramgürler Hatice Şanlı Nahide Onsun |
| author_sort | Sinem Örnek |
| collection | DOAJ |
| description | Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed. However, increasing intervals between treatments or switching to alternative therapies may be preferable in stable diseases. Most importantly, all patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues. |
| first_indexed | 2024-04-10T12:39:11Z |
| format | Article |
| id | doaj.art-18779255e8a74eecb48c7e428e6c19d0 |
| institution | Directory Open Access Journal |
| issn | 2651-5164 |
| language | English |
| last_indexed | 2024-04-10T12:39:11Z |
| publishDate | 2022-03-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Turkderm Turkish Archives of Dermatology and Venereology |
| spelling | doaj.art-18779255e8a74eecb48c7e428e6c19d02023-02-15T16:14:24ZengGalenos Publishing HouseTurkderm Turkish Archives of Dermatology and Venereology2651-51642022-03-015611610.4274/turkderm.galenos.2021.47817Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemicSinem Örnek0https://orcid.org/0000-0002-1536-6035Aslı Bilgiç1https://orcid.org/0000-0001-7910-7908Serkan Yazici2https://orcid.org/0000-0001-6407-0962Dilek Bayramgürler3https://orcid.org/0000-0001-6617-0019Hatice Şanlı4https://orcid.org/0000-0002-2960-3126Nahide Onsun5https://orcid.org/0000-0001-6259-0219University of Health Sciences Turkey, Dışkapı Yıldırım Beyazit Training and Research Hospital, Clinic of Dermatology, Ankara, TurkeyAkdeniz University Faculty of Medicine, Department of Dermatology, Antalya, TurkeyUludağ University Faculty of Medicine, Department of Dermatology, Bursa, TurkeyKocaeli University Faculty of Medicine, Department of Dermatology, Kocaeli, TurkeyAnkara University Faculty of Medicine, Department of Dermatology, Ankara, TurkeyBezmialem Vakıf University Faculty of Medicine, Department of Dermatology, İstanbul, TurkeyCoronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed. However, increasing intervals between treatments or switching to alternative therapies may be preferable in stable diseases. Most importantly, all patients with PCL should be ensured to comply with general protection measures as long as the pandemic continues.https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-47817&look4=primary cutaneous lymphomacovid-19management |
| spellingShingle | Sinem Örnek Aslı Bilgiç Serkan Yazici Dilek Bayramgürler Hatice Şanlı Nahide Onsun Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic Turkderm Turkish Archives of Dermatology and Venereology primary cutaneous lymphoma covid-19 management |
| title | Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic |
| title_full | Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic |
| title_fullStr | Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic |
| title_full_unstemmed | Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic |
| title_short | Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic |
| title_sort | primary cutaneous lymphomas and coronavirus disease 2019 a critical overview of primary cutaneous lymphoma management in pandemic |
| topic | primary cutaneous lymphoma covid-19 management |
| url | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-47817&look4= |
| work_keys_str_mv | AT sinemornek primarycutaneouslymphomasandcoronavirusdisease2019acriticaloverviewofprimarycutaneouslymphomamanagementinpandemic AT aslıbilgic primarycutaneouslymphomasandcoronavirusdisease2019acriticaloverviewofprimarycutaneouslymphomamanagementinpandemic AT serkanyazici primarycutaneouslymphomasandcoronavirusdisease2019acriticaloverviewofprimarycutaneouslymphomamanagementinpandemic AT dilekbayramgurler primarycutaneouslymphomasandcoronavirusdisease2019acriticaloverviewofprimarycutaneouslymphomamanagementinpandemic AT haticesanlı primarycutaneouslymphomasandcoronavirusdisease2019acriticaloverviewofprimarycutaneouslymphomamanagementinpandemic AT nahideonsun primarycutaneouslymphomasandcoronavirusdisease2019acriticaloverviewofprimarycutaneouslymphomamanagementinpandemic |